Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The transcriptional activator hypoxia-inducible factor (HIF) is a vital arbitrator in the performance of cellular responses lacking oxygen supply in aerobic organisms. Because these compounds are capable of enhancing the organism's capacity for molecular oxygen transport, they possess great potential for abuse as a performance-enhancing agent in sports. A comprehensive study of the metabolic conversion of the most popular HIF stabilisers such as IOX2, IOX3 and IOX4 using equine liver microsomes (in vitro) is reported. The parents and their metabolites were identified and characterised by liquid chromatography-mass spectrometry in negative ionisation mode using a QExactive high-resolution mass spectrometer. Under the current experimental condition, a total of 10 metabolites for IOX2 (three phase I and seven phase II), nine metabolites for IOX3 (four phase I and five phase II) and five metabolites for IOX4 (three phase I and two phase II) were detected. The outcome of the present study is as follows: (1) all the three IOX candidates are prone to oxidation, results in subsequent monohydroxylated, and some dihydroxylated metabolites. (2) Besides oxidation, there is a possibility of hydrolysis and de-alkylation, which results in corresponding carboxylic acid and amide, respectively. (3) The glucuronide and sulphate conjugate of the parent drugs as well as the monohydroxylated analogues were observed in this study. The characterised in vitro metabolites can potentially serve as target analytes for doping control analysis.

Download full-text PDF

Source
http://dx.doi.org/10.1002/dta.3000DOI Listing

Publication Analysis

Top Keywords

phase phase
12
hypoxia-inducible factor
8
stabilisers iox2
8
iox2 iox3
8
iox3 iox4
8
doping control
8
three phase
8
phase metabolites
8
metabolites
6
phase
6

Similar Publications

Background: The success of disease registry systems (DRSs) depends on developing software that aligns with the registry's specific needs.

Objective: This study focuses on localising the Checklist with Items for Patient Registry sOftware Systems (CIPROS) to facilitate the DRS assessment.

Method: This applied and cross-sectional study was carried out in 2023 in six phases.

View Article and Find Full Text PDF

Although improving the charging cutoff voltage is an effective strategy to increase its capacity, LiCoO ("LCO") undergoes rapid capacity decay due to severe structural and interface degradations at high voltages. Herein, we proposed a multifunctional surface modification by coating nano-sized entropy materials (Li-La-Ti-Zr-Co-O, Nano-MEO). Nano-MEO rivets were constructed on the surface of LCO, which stabilized the fragile surface.

View Article and Find Full Text PDF

Background: To assess the efficacy and safety of tenecteplase in patients presenting within 24 hours of symptom onset with a large vessel occlusion and target mismatch on perfusion computed tomography.

Methods: ETERNAL-LVO was a prospective, randomized, open-label, blinded end point, phase 3, superiority trial where adult participants with a large vessel occlusion, presenting within 24 hours of onset with salvageable tissue on computed tomography perfusion, were randomized to tenecteplase 0.25 mg/kg or standard care across 11 primary and comprehensive stroke centers in Australia.

View Article and Find Full Text PDF

Droughts are increasing with climate change, affecting the functioning of terrestrial ecosystems and limiting their capacity to mitigate rising atmospheric CO levels. However, there is still large uncertainty on the long-term impacts of drought on ecosystem carbon (C) cycling, and how this determines the effect of subsequent droughts. Here, we aimed to quantify how drought legacy affects the response of a heathland ecosystem to a subsequent drought for two life stages of Calluna vulgaris resulting from different mowing regimes.

View Article and Find Full Text PDF

Purpose: To study the efficacy and safety of pro re nata regimen of brolucizumab, without loading dose, in treatment-naive patients with neovascular age-related macular degeneration (nAMD).

Case Series: Retrospective, observational study. We included all consecutive patients diagnosed with treatment- naïve nAMD undergoing Brolucizumab in Humanitas eye clinic, Turin, Italy between April 2022 and May 2023.

View Article and Find Full Text PDF